-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Surgery Partners, Lowers Price Target to $21

Benzinga·03/05/2026 15:37:23
Listen to the news
UBS analyst A.J. Rice maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $29 to $21.